NAPSRX CNPR EXAM | QUESTIONS WITH 100% CORRECT ANSWERS (REVISED 18TH EDITION) |VERIFIED | UPDATED, NAPSRX / CNPR EXAM NEWEST VERSION 2026/2027 GRADED A+, NAPSRX CNPR EXAM: KEY CONCEPTS AND QUESTIONS WITH 100% CORRECT ANSWERS | VERIFIED | L

NAPSRX CNPR EXAM | QUESTIONS
WITH 100% CORRECT ANSWERS
(REVISED 18TH EDITION) |VERIFIED |
UPDATED, NAPSRX / CNPR EXAM
NEWEST VERSION 2026/2027 GRADED
A+, NAPSRX CNPR EXAM: KEY
CONCEPTS AND QUESTIONS WITH
100% CORRECT ANSWERS | VERIFIED |
LATEST UPDATE
whatRdoesRaRSTATRorderRmean?R-
RCORRECTRANSWERaRdrugRneededRimmediatelyRandRgivenRonlyRonce




whatRinformationRdoesRtheRoverdosageRsectionRofRtheRlabelingRprovide?R-
RCORRECTRANSWERsigns,RsymptomsRandRtreatmentRofRacuteRoverdoses




typesRofRdrug-drugRinteractions:R-
RCORRECTRANSWERduplication,RoppositionR(antagonism)RandRalterationR(p.51)




toleranceRvsRresistanceR-
RCORRECTRANSWERtoleranceRisRtheRdiminishedRresponseRtoRaRdrug;RresistanceRisRtheRcellsRabilityR


toRresistRtheReffectsRofRtheRdrugRonRthem.



abbreviatedRnewRdrugRapplicationR(ANDA)R-
RCORRECTRANSWERtheRprocessRbyRwhichRapplicantsRmustRscientificallyRdemonstrateRtoRtheRFDARt


hatRtheirRgenericRproductRisRbioequivalentRtoRorRperformsRinRtheRsameRwayRasRtheRinnovatorRdrug,
RnoRduplicateRtestingR(p.R75)

,theRHatch-WaxmanRActRofR1984R-RCORRECTRANSWER-
A.K.A.RDrugRPriceRCompetitionRandRPatentRRestorationRAct

-
madeRitReasierRtoRbringRgenericRdrugsRtoRtheRmarketRbyRrequiringRtheRFDARtoRonlyRlookRatRbioavail
abilityRstudiesRinRorderRtoRapproveRanRANDA.

-gaveRprotectionRtoRtheRresearchRbasedRmanufacturersRbyRprovidingRaR30-
monthRautomaticRcoolingRoffRperiodRonceRanRANDARisRchallengedRforRpatentRinfringementR(p.R75)



fourRbasicRtransportRmechanismsR-
RCORRECTRANSWERpassiveRdiffusion,RfacilitatedRdiffusion,RactiveRtransport,RandRpinocytosisR(p.R9


5)



potencyRvsRefficacyR-
RCORRECTRANSWERpotency:RamountRofRdrugRnecessaryRtoRproduceRdesiredReffect



efficacy:RmagnitudeRofRmaximalRresponseRthatRcanRbeRreceivedRfromRaRdrug

*efficacyRisRalmostRalwaysRmoreRimportantRthatRpotency*R(p.R106)



theRfourRphasesRofRclinicalRtrialsR-RCORRECTRANSWERphasesRI-IVR(P.R124-126)



KeyRPartsROfRARClinicalRPaperR(5)R-
RCORRECTRANSWERAbstract,RIntroduction,Rmethods,Rresults,Rdiscussion/conclusionsR(p.R128-


129)



reliabilityRvsRvalidityR-RCORRECTRANSWERreliabilityR=RconsistencyRandRvalidityR=Raccuracy

(p.R138;R143)



samplingRerrorRvsRselectionRbiasR-
RCORRECTRANSWERsamplingRerrorRisRunbiasedRandRisRrandomlyRchosenRfromRtheRpopulation.R

,selectionRbiasRisRwhenRtheRsampleRwasRspecificallyRchosenRbasedRonRparticularRcharacteristicsR(p.
142-143)



independentRvsRdependentRvariableR-
RCORRECTRANSWERAnRindependentRvariableRisRtheRoneRthatRinfluencesRtheRvariation.RARdepende


ntRvariableRisRtheRvariableRbeingRtestedRandRmeasuredRinRaRscientificRexperimentR(theRresultRofRap
plyingRtheRindependentRvariable).



DrugRUtilizationRReviewR(DUR)RprogramsR-RCORRECTRANSWER-
involveRretrospectiveRmonitoringRofRphysicians'RprescribingRpatterns

-moreRthanR90%RofRHMOsRrequireRDURs

-nowadaysRmostlyRmonitorsRcostRsavingsR(p.R181)



opportunityRcostR-
RCORRECTRANSWERbasedRonRtheRpremiseRthatRallRresourcesRareRscarce,RandRthereforeReveryRtime


RweRchooseRtoRuseRaRresourceRitRreducesRtheRpossibilityRofRitRbeingRusedRinRanotherRway.




whatRtypeRofRDTCRadvertisingRisRtheRonlyRlegalRformRinREurope?R-RCORRECTRANSWERDisease-
stateRorRunbrandedRadsR(providesRpublicRinformationRonRaRdisease,RnotRaRdrug)

(p.R223)



canRpharmRsalesRrepsRofferRdoctorsRmeals?R(PhRMARcode)R-
RCORRECTRANSWERcompanyRrepsRcanRonlyRofferRoccasionalRmealsRasRlongRasRtheyRareRmodest,Ran


dRonlyRofferedRinRanRoffice/hospitalRsettingRinRconjunctionRwithRanReducationalRpresentation.R(p.R2
28)



FAQRaboutRtheRPhRMARcodeR-RCORRECTRANSWERp.R268-274



UrologyRandRsellingRtoRUrologistsR-RCORRECTRANSWERp.R300-301

, whatRisRaRMedicalRScienceRLiaisonR(MLS)?R-RCORRECTRANSWERtheyRserveRasReducatorsRandRfield-
basedRmedicalRresources.RtheyRinterfaceRbetweenRtheirRcompanyRandRhealthcareRleaders.



pushRthroughRvsRpullRthroughRsalesRstrategiesR-RCORRECTRANSWER-Rpush-
throughRrefersRtoRtheRcompany'sRoverallReffortsRtoRdemonstrateRclinicalRefficiencyRandRefficacyRan
dRcostReffectivenessRofRaRproduct.R

-Rpull-
throughRgeneratesRdemandRforRtheRproduct,RusuallyRinRwaysRconsistentRwithRtheRhealthRplansRgoa
lsRandRguidelines.R(p.R311)



drugRlabelingRrequirementsRFDAR-RCORRECTRANSWERhttps://www.fda.gov/about-fda/oncology-
center-excellence/how-do-i-use-prescription-drug-labeling#Section-10



WhatRisRpredictiveRvalidity?R-
RCORRECTRANSWERtheRabilityRofRanRindicatorRtoRcorrectlyRpredictRanRoutcome.




whatRareRsomeRofRtheRcriteriaRthatRinfluenceRtheRdecisionRtoRuseRmassRadvertisingRinRpharmaceuti
calRmarketing?R-RCORRECTRANSWER*theRsizeRofRtheRtargetRpatientRpopulation

theRchronicityRofRtheRdiseaseRstate

theRrelevanceRofRthatRdiseaseRstateRtoRitsRsufferers

theRavgRvalueRofRaRpatientRtakingRmedication



accordingRtoRtheRAMARguidelines,RwhoRshouldRacceptRsubsidiesRforRcontinuingRmedicalReducation
Rconferences?R-RCORRECTRANSWERconferenceRsponsors




whoRisRtheRdecisionRmakerRinRpharmaceuticalRsales?R-RCORRECTRANSWERtheRphysician